iXensor Co. Ltd. is based in Taipei, Taiwan and was founded in 2012. Our three co-founders, Alan Tsai, the CEO, Jerry Chen, the CMO, Carson Chen, the CTO, first met in Stanford-Taiwan Biomedical Fellowship Program (STB) and came up with the idea of PixoTest technology. This breakthrough idea sparked global interest and attention. Soon, the company became over 50 ambitious members strong, bringing this mobile health solution to life.

The iXensor family consists of 8 PhD and over 40 energetic and talented members who all devote themselves to develop the hardware and software system for a wide-range of IVD products, to provide a solution that is innovative and reliable.

We operate a Quality Management System which complies with the requirements of ISO 13485:2003 and EN ISO 13485:2012. Our products fulfill the requirements of Directive 98/97/EC on in vitro diagnostic medical devices. We deliver innovative products without compromising quality control.


Facilitate data-driven healthcare with instant medical tests and seamless data synchronization.


Make quality healthcare accessible and timely.

Core Technology & Capability


The PixoTest® technology utilizes the lighting and image sensing module of the smartphone (or mobile device) to detect the color change reaction on the biochemical test strip (US patent granted).

The image of the test strip is captured by the front camera of the smartphone and analyzed via the measurement algorithm to turn out a quantified or semi- quantified result. With the control on light sources with multiple wavelengths from the screen lighting module of the smartphone, the PixoTest® Innovation can be applied on different biomarker measurements.


iXensor’s globally-exclusive PixoTest® technology can turn mobile devices into In Vitro Diagnostic Medical Devices. With PixoHealth App, test readings can be measured, recorded and uploaded to the cloud “PixoHealth Hub”. This enables users to monitor their conditions of diabetes, cardiovascular diseases, women health problems, or infectious diseases.

The data can also be used for patients’ self-management, medical professionals’ analysis or the government’s appraisal of disease control policies



  • PixoTest POCT System (Lipid, A1c) got CE certificate.
  • Chosen as the representative of Taiwan to participate the Mobile World Congress (MWC) in Spain.
  • Presented HbA1c monitoring system at Advanced Technologies & Treatments for Diabetes (ATTD), Vienna.
  • iXensor chosed to be the CES representative of Taiwan.
  • Eveline Smart Fertility System won CES "the best of babyTech" award.


  • PixoTest POCT got NGSP certificate.
  • PixoTest Blood Glucose Monitoring System (BGMS) got FDA 510(k) clearance
  • Eveline Smart Fertility System awarded Taiwan Excellence Award, Taiwan.
  • Eveline Smart Fertility System awarded Good Design Award, Japan.
  • PixoTest BGMS awarded Digital Health Award.
  • PixoTest BGMS's clinical trial published on national journal, JDST


  • PixoTest® BGMS pass Geman IDT clinical trial
  • PixoTest® BGMS Taiwan TFDA certified


  • Pass ISO unannounced audit
  • GMP certified
  • Awarded first US patent


  • Finalist of 2014 Medica eHealth Innovation Award
  • PixoTest® BGMS got CE certificate
  • ISO 13485 certificated


  • iXensor established


Management Team

Alan Tsai

Chief Excecutive Officer
  • Ph. D., Chemistry, NCHU
  • Visiting Scholar, Stanford
  • Co-Founder, Bionime

Carson Chen

Chief Technology Officer
  • Ph.D., Electrical Engineering, NTU
  • Visiting Scholar, Mechanical Engineering, MIT
  • Postdoctoral Scholar, Bioengineering, Caltech
  • Visiting Scholar, Stanford

Jerry Chen

Chief Medical Officer
  • M.D., Kaohsiung Medical University
  • M.S. & Ph.D., Biomedical Engineering, NCKU
  • Director, Urology & Uro-oncology, Beigang Hospital, China Medical University
  • Visiting Scholar, Stanford

Eric Chen

Vice President of Sales
  • Executive MBA of NSYSU
  • GM, China of Bionime
  • Sales Director, APAC of Bionime

Claire Tsai

Director of Business Development
  • MBA, Johnson Graduate School of Management, Cornell University
  • Investment Director, BioEngine Technology Development
  • Project Manager, TTY BioPharm
  • Investment Manager, CDIB BioScience Management

Gabriel Chao

Director of Business Development
  • Ph.D., Electrical Engineering, National Taiwan University
  • Visiting Scholar, Center for Cardiovascular Technology, School of Medicine, Stanford University
  • Senior RD Director, iXensor, Co Ltd
  • Adjunct Assistant Professor, Electronic Engineering Dept, National Taiwan University of Science and Technology